Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- IMU
- Why IMU is a multi multi bagger
IMU
imugene limited
Add to My Watchlist
7.69%
!
1.4¢

Why IMU is a multi multi bagger, page-12151
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
-
Share
It’s difficult I know. You start to doubt your own better judgement. Close friends and family members begin to cast dispersions over your choice of investment decision. IMU once the rain giver in your family’s eyes is now the villain, responsible for financial loss, heartache and potential failure, in the eyes of those you love the most.
“Is it all a pipe dream?” They question behind your back.
“When’s it going to happen Dad?” he asks, sitting in the back seat of your car awaiting your every response.
You feel like saying,
“It’s all set to happen soon son”.However a considerably more measured voice from within counsels you to suggest,
“It is all on track, set to happen, but the timing as yet remains unclear.”“But if it’s as good as everyone including you are saying Dad, why isn’t this public knowledge? Isn’t it time to save as many patients as we can? Isn’t it time to let the world know of this remarkable discovery. To let them know there is light at the end of the tunnel for those with late stage cancer?” He questions, as if another's life depends on it.
He has a point. New cancer cases are expected to rise by 47% from 2020 to 2040, across the globe. Isn’t it time Imugene and Big Pharma alongside them hopped on their bikes?
Enter Professor Fong and his wonder drugs, CF33 and Vaxinia
This week Imugene did hop on their bike to travel “Down Under”. In doing they took one step closer to assisting cancer patients in the future, as news from their oncolytic virus founder Professor Yuman Fong broke a new dawn. This week on a roadshow tour to Australia Professor Fong proceeded to excite IMU shareholders country wide when noting CF33 and its potent parental virus Vaxinia were potentially capable of curing any cancer, if dosed at their optimal biological dose rate. Having cured mice of all cancers against the NCI 60 pre-clinically, Professor Fong stated everything he saw in trials with animals, he was now seeing within humans. As for his current oncolytic trials Fong noted “we are already seeing unequivocal evidence that we are killing cancer in humans.”
The good news is the renowned Professor Fong is overseeing clinical trials that are increasing at an increasing rate, both here in Australia and throughout the US. As more and more cancer patients and oncologists hear of the Vaxinia clinical trial they are lining up in queues to participate. Now 9 sites have registered to join this ground breaking trial. As a result Professor Fong expressed elation this week at the speed the trial was progressing. For at the same time some patients are being dosed both intramurally and intravenously with Vaxinia, others are being dosed in a combination of Merck’s Keytruda and Vaxinia, all at higher dosage rates than Cohorts 1 and 2 in the ongoing Vaxinia trial. Given the higher dosage of the virus being metered out now to solid tumour patients, Professor Fong anticipates seeing even stronger efficacy than has been visualised thus far. This is indeed great news for those yet to receive Vaxinia, given the virus has already exhibited signs of efficacy in Cohorts 1 and 2 of the trial, despite the minuscule dosage rates imposed by the FDA to date.
And what’s all the talk surrounding Her Vaxx?
Aside from the fever surrounding the aforementioned CF33 and Vaxinia Imugene does appear poised to obtain a slice of the cancer market pie. The global oncology market was recently valued at US$ 286.04 billion in 2021 and is expected to reach over US$ 581.25 billion by 2030, forecast to grow at a noteworthy CAGR of 8.2% from 2022 to 2030.
Chart courtesy of Precence Research
Imugene’s leading B cell candidate Her Vaxx is in Phase two trials with Merck’s Keytruda, a monoclonal antibody that earns the Big Pharma around $17BN USD per annum. Keytruda’s patent life is running out in a few years, and Her Vaxx could provide a good combination for Keytruda, not just as an extension to the blockbusters runway, but as a safety enhancer to Keytruda. It is well known that unlike Her Vaxx, Keytruda produces extensive side effects in cancer patients. Whilst another advantage of a Her Vaxx Keytruda combination is that apart from Her Vaxx’s excellent safety parameters, the drug was found to extend the life of Her 2 expressing patients with late stage gastric cancer by up to 6 months over and above the standard of care, chemotherapy, in a recent Phase 2 clinical trial conducted by Imugene. Of note is the fact that in the current combination trial patients are being dosed with twice the dose rate of Her Vaxx than previously, a factor researchers suggest could produce even longer life expectancy. Researchers believe this time around the anticipated increased antibody production resultant from higher dosage levels of Her Vaxx may stimulate the cancer patients immune system even more in the fight against cancer, than it did in Her Vaxx’s much heralded initial Phase 2 trial.
Is Her Vaxx about to be licensed out?
This probably isn’t such a bad question for IMU shareholders. Imugene Chairman Paul Hopper last week stressed in a series of company held “March Roadshows” his commercial strategy was to create compelling scientific evidence for Imugene’s drugs, and in doing so sell them in the Phase 2 stage of their clinical development. Hopper at the time went on to say Imugene was not in the business of marketing or selling their drugs and therefore in taking them to the Phase 3 stage of clinical development. In analysing a potential value for the B Cell vaccine known as Her Vaxx many point to another Her 2 expressing vaccine known as Herceptin, owned and marketed by the big Pharma Roche. Herceptin, a market leader in the breast cancer space reached peak sales of $7BN USD in 2019 and is still netting billions each year in annual revenue. If Herceptin is any guide Her Vaxx must be valued at billions of USD, as not only is Her Vaxx a safer drug than Herceptin, it promises to be just as effective in extending patient lives, once they are administered with the optimal biological dose of the drug.
How many billions of dollars is dependent largely on the business acumen of Imugene’s Chief of Business Monil Shah, who along with Hopper and the company’s Chief Financial Officer Mike Tonroe, have been assigned the task of cutting a deal with Big Pharma in the drugs now phase 2 development stage. Obviously much is sure to depend on the current Her Vaxx/Keytruda combination trial results, but keep in mind sound cancer drugs sell for between 3 to 4 times annualised peak sales. Her Vaxx’s extensive trademark coverage in addition to its potential to act in breast, gastric and other lucrative cancer markets, are all factors assisting Shah and his team to secure a pultis for IMU shareholders, when all is said and done. Fingers crossed….
Imugene’s B cell value is enhanced by the company’s second B cell candidate PD1 Vaxx, a drug that recently exhibited strong results in a Phase 1 clinical trial for late stage lung cancer patients in Melbourne. The drugs administration resulted in a complete response for one patient, who is now cancer free, as well as many partial responses and disease stabilisation outcomes for these very sick patients. The PD1 Vaxx results have led to a supply agreement being solidified with the Big Pharma Roche, who is soon to supply their successful Tercentriq drug with Imugene’s PD1 Vaxx in a trial for lung cancer patients. Lung cancer is a prevalent form of cancer, particularly in Asia and throughout the US, where patients up til now have poor life expectancy when presenting in the late stages of their disease. PD1 Vaxx’s advancement to this combination trial with Roche is not only proof of concept for Imugene’s B cell platform, it is another string to Monil Shah’s bow, when it comes to securing a potential deal with a Big Pharma suitor.
What about Vaxinia, is the world soon to awaken to Professor Fong’s revelations?
Talking with and listening to Professor Yuman Fong this week my mind drifted back to countless Economics and History lectures pertaining to the Industrial Revolution. Wikipedia notes the Industrial Revolution marked a major turning point in history. Comparable only to humanity's adoption of agriculture with respect to material advancement, the Industrial Revolution influenced in some way almost every aspect of daily life. Given cancers grip on our current life expectancy, health outcomes and everyday life, could Professor Fong’s medical breakthroughs bring with them a similar transformation in the way both cancer sufferers and patients are treated in general? Is medicine today to benefit in much the same way as our economy did a few hundred years ago?
This week only a handful of IMU shareholders would have listened to Professor Fong’s revelations. Given Imugene’s opposition to self promotion and lack of media, marketing and communications personnel, rest assured not many in the general public would have heard of Fong’s declarations either. Likewise although Professor Fong went on late night US TV in 2022 to say he is convinced one day his wonder drugs are destined to become human therapy, (i.e., in combination with a myriad of cancer treatment arms), there was no mention of Imugene, and no mention of when. Is this such a bad thing? Maybe, maybe not. Imugene at present remain focused on dosing as many patients with Vaxinia as they can in rapid time. From the outside looking in they appear to be of the mind that in due course public awareness and share price rises shall follow accordingly. Either way if you are a critic of this approach, as I often have been, or a supporter, as many of you are, Professor Fong’s presentation to shareholders was of itself transformational. His notification to IMU shareholders that his clinical trial results have been sent to the lab for biopsies and independent analysis, is sure to set the cat amongst the pigeons in weeks and months to come. If as he suggests CF33 and/or Vaxinia have been found to reduce the size of solid tumours within cancer patients at low doses, then the world opens up, for not only him, but for Imugene as well. Never before have solid tumours in cancer patients been effectively treated by an oncolytic virus when administered intravenously, as are the patients in Imugene’s current Vaxinia trial. If these results are promising at low doses, how effective is CF33 and/or Vaxinia going to be at even higher dosage rates? Highly effective, is the answer I gleaned from speaking personally with Professor Fong in late 2022 and on Tuesday last. He is of the opinion the current Cohort 3 in Imugene’s Vaxinia Trial is being dosed at a rate sure to produce efficacy, given the results he has seen thus far.
Do you, IMU shareholders or cancer patients need to know more? If so why? Do you not believe the Professor and Imugene? Are their protestations perceived by the public to be a case of the boy who cried wolf? Or are these sentiments from retail investors symptomatic of a dwindling IMU share price? In short who cares. I for one have been wrong, wrong, and yes wrong when it comes to the IMU share price in recent months. Having forecast the rise to 62 cents AUD, I for one did not forecast a crash down to 12 cents. I envisaged fund managers and institutional investors realising IMU’s true potential, and following Blackrock, Norges Bank, State Street and Vanguard onto the the IMU share register in droves. Perhaps I was ensconced in the company’s fundamentals, and as a consequence disconnected from the local ASX 200 market, which has subsequently pummelled the stock. That said I do continue to buy the stock. I do agree with the price targets set by leading healthcare analysts. I do continue to trust in Professor Yuman Fong. And most importantly I do continue to believe that sooner rather than later cancer patients both here and in the US are to present to their oncologists with signs of improvement. Some are set to see their disease stabilise, and in my opinion some are even soon to be cured of cancer, as has been the case in Imugene’s Her Vaxx and PD1 Vaxx trials. And isn’t that a beautiful thing….
DYOR … Seek investment advice as and when required..Opinions only
Last edited by Watmighthavben: 19/03/23
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M |
Open | High | Low | Value | Volume |
1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 788815 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 13241534 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 406921 | 0.013 |
52 | 13104870 | 0.012 |
37 | 7099788 | 0.011 |
51 | 15783275 | 0.010 |
13 | 2798488 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 12761766 | 25 |
0.015 | 7786799 | 32 |
0.016 | 6497205 | 27 |
0.017 | 9090240 | 16 |
0.018 | 2944932 | 17 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |